Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Cancer risk in multiple sclerosis: findings from British Columbia, Canada.
Medical marijuana: clearing away the smoke.
Teva Presents New Data Which Demonstrate Reduction of Injection-Related Adverse Events with the Less Frequent Dosing of Three-times-a-week COPAXONE® (glatiramer acetate injection) 40 mg Compared to Daily COPAXONE® 20 mg
Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome.
Involvement of oxidative stress on the impairment of energy metabolism induced by A beta peptides on PC12 cells: protection by antioxidants.
"Tell me what you want, what you really really want….": asking people with multiple sclerosis about enhancing their participation in physical activity.
CHMP assessment report for Sovrima (International nonproprietary name: idebenone)
Genzyme’s Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis
Genmab announces details of planned ofatumumab Phase II study in multiple sclerosis
Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
Pharmaceutical approval update.
The delta-subunit of the epithelial sodium channel (ENaC) enhances channel activity and alters proteolytic ENaC activation.
Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.
Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders.
Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.
Phenytoin (Dilantin) and acupuncture therapy in the treatment of intractable oral and facial pain.
Vaccines and the Risk of Multiple Sclerosis and Other Central Nervous System Demyelinating Diseases.
Multiple Sclerosis: Vitamin D and calcium as environmental determinants of prevalence (A Viewpoint)
Parent-of-origin effect in multiple sclerosis: observations in half-siblings.
Microvesicles: novel biomarkers for neurological disorders.
Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects with Multiple Sclerosis
Demyelination: the role of reactive oxygen and nitrogen species.
Santhera enters agreement with Columbia University to investigate additional potential of Catena® in MELAS
The effects of intrathecal rituximab on biomarkers in multiple sclerosis.
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat.

Pages